Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
时间:2024-06-26 06:18:52 阅读(143)
Lupin gets USFDA approval for suspension to treat allergic conjunctivitis
Global pharma major Lupin Limited on Wednesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.2 percent.
The approval has been granted to market a generic equivalent to the reference listed drug (RLD) Alrex Ophthalmic Suspension, 0.2%, of Bausch & Lomb Inc. The product will be manufactured at Lupin’s Pithampur facility in India.
Loteprednol Etabonate Ophthalmic Suspension, 0.2% (RLD Alrex), had estimated annual sales of USD 29.1 million in the U.S. (IQVIA MAT October 2023).
分享到:
温馨提示:以上内容和图片整理于网络,仅供参考,希望对您有帮助!如有侵权行为请联系删除!
猜你喜欢
- Global Markets- Stocks, euro steady ahead of ECB, crude tumbles
- Diwali 2021- Bank Nifty to cross 42,000 before Diwali; watch out for these things in Samvat 2078
- L&T Construction bags significant order for its Buildings & Factories business from HITES
- Global Markets- Shares set for weekly gain, Treasury yields fall as investor optimism
- Global Markets- Stocks sink on fears for global economy, capping worst H1 on record
- Dow, S&P 500 eye higher open as regional banks rise; key inflation data awaited
- Kaynes Technology IPO set to open on November 10
- Learning Microsoft Office can help you get your dream job
- Dow, S&P 500 eye higher open as regional banks rise; key inflation data awaited